Reduced total antioxidant level and increased oxidative stress in patients with deficit schizophrenia: A preliminary study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 45, Issue , 2013, Pages 144-149

  Albayrak, Yakup ^a   Ünsal, Cüneyt ^b   Beyazyüz, Murat ^c   Ünal, Ahmet ^d   Kuloǧlu, Murat ^e  

^a Kirklareli State Hospital   (Turkey)

^b NAMIK KEMAL UNIVERSITY   (Turkey)

^c Golbasi Hasvak State Hospital   (Turkey)

^d GAZIANTEP UNIVERSITY   (Turkey)

^e AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Antioxidant; Deficit schizophrenia; Oxidative stress

Indexed keywords

ANTIOXIDANT;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; DEFICIT SCHIZOPHRENIA; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; OXIDATIVE STRESS INDEX; SCHIZOPHRENIA; TOTAL ANTIOXIDANT POTENTIAL; TOTAL PEROXIDE LEVEL;

ANTIOXIDANT; BPRS; BRIEF PSYCHIATRIC RATING SCALE; DEFICIT SCHIZOPHRENIA; DS; HC; HEALTHY CONTROL; NDS; NONDEFICIT SCHIZOPHRENIA; OSI; OXIDATIVE STRESS; OXIDATIVE STRESS INDEX; SANS; SAPS; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOMS; SCALE FOR THE ASSESSMENT OF POSITIVE SYMPTOMS; SCID-I; SD; SPSS; STANDARD DEVIATION; STATISTICAL PACKAGE FOR THE SOCIAL SCIENCES; STRUCTURED CLINICAL INTERVIEW FOR DSM-IV AXIS I; TAOP; TOTAL ANTIOXIDANT POTENTIAL; TOTAL PEROXIDE LEVELS; TPEROX;

ADOLESCENT; ADULT; ANTIOXIDANTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PEROXIDES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SYMPTOM ASSESSMENT;

EID: 84878851248     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.04.020     Document Type: Article

References (77)

1. Al-chalabi B.M., Thanoon A.J., Ammed F.A. Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients. Neuropsychobiology 2009, 59:8-11.
2. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Association, Washington, DC. 4th ed.
3. Ames B.N. Low micronutrient intake may accelerate the degenerative diseases of aging through allocation of scarce micronutrients by triage. Proc Natl Acad Sci U S A 2006, 103:17589-17594.
4. Andreasen N.C. Scale for the assessment of negative symptoms (SANS) 1984, College of Medicine, University of Iowa, Iowa City, IA.
5. Andreasen NC.scale for the assessment of positive symptoms (SANS) Iowa City 1984, College of Medicine, University of Iowa, IA.
6. Arvindakshan M., Ghate M., Ranjekar P.K., Evans D.R., Mahadik S.P. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res 2003, 62:195-204.
7. Atmaca M., Tezcan E., Kulgolu M., Ustundang B., Kirtas O. The effect of extract of Ginkgo biloba addition to Olanzapine therapeutic effect and antioxidant enzyme levels in patients with schizophrenia. Psychiatry Clin Neurosci 2005, 59:652-656.
8. Berg D., Youdim M.B., Riederer P. Redox imbalance. Cell Tissue Res 2004, 318:201-213.
9. Bitanihirwe B.K., Woo T.U. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev 2011, 35(3):878-893.
10. Bošković M., Vovk T., Kores Plesničar B., Grabnar I. Oxidative stress in schizophrenia. Curr Neuropharmacol 2011, 9(2):301-312.
11. Carpenter W.T., Heinrichs D., Wagman A.M. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988, 145:578-583.
12. Carpenter W.T., Arango C., Buchanan R.W., Kirkpatrick B. Deficit psychopathology and a paradigm shift in schizophrenia research. Biol Psychiatry 1999, 46:352-360.
13. Citak S., Oral E.T., Aker A.T., Senocak M. Reliability and validity of the schedule for deficit syndrome in schizophrenia. Turk Psikiyatri Derg 2006, 17(2):115-127.
14. Corapcioglu A., Aydemir O., Yildiz M. Structured clinical interview for DSM-IV (SCID-IV), Turkish version (Turkish) 1999, Hekimler Yayin Birligi, Ankara, Turkey.
15. Corbetta M., Patel G., Shulman G.L. The reorienting system of the human brain: from environment to theory of mind. Neuron 2008, 58:306-324.
16. Dadheech G., Mishra S., Gautam S., Sharma P. Evaluation of antioxidant deficit in schizophrenia. Indian J Psychiatry 2008, 50:16-20.
17. Dakhale G., Khanzode S., Khanzode S., Saoji A., Khobragade L., Turankar A. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 2004, 49:205-209.
18. Davies K.J. Oxidative stress, antioxidant defenses, and damage removal, repair, and replacement systems. IUBMB Life 2000, 50:279-289.
19. Eaton W.W., Martins S.S., Nestadt G., Bienvenu O.J., Clarke D., Alexandre P. The burden of mental disorders. Epidemiol Rev 2008, 30:1-14.
20. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004, 37:112-119.
21. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005, 38:1103-1111.
22. Erkoc S., Arkonaç O., Atakli C. Ozmen E Negatif semptomlari deǧerlendirme ölçeǧinin güvenirlirliǧi ve geçerliliǧi. Düşünen Adam 1991, 4:16-19.
23. Erkoc S., Arkonaç O., Atakli C., Ozmen E. Pozitif semptomlari deǧerlendirme ölçeǧinin güvenirlirliǧi ve geçerliliǧi. Düşünen Adam 1991, 4:20-24.
24. Evans D.R., Parikh V.V., Khan M.M., Coussons C., Buckley P.F., Mahadik S.P. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot Essent Fatty Acids 2003, 69:393-399.
25. Fenton W.S., Dickerson F., Boronow J., Hibbeln J.R., Knable M.A. Placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 2001, 158:2071-2074.
26. First M.B., Spitzer R.L., Gibbon M. Structured clinical interview for DSMIV axis I disorders (SCID), clinician version 1996, American Psychiatric Press, Washington, DC.
27. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state examination: user's guide 2001, Psychological Assessment Resources, Inc., Odessa, FL.
28. Galderisi S., Maj M. Deficit schizophrenia: an overview of clinical, biological and treatment aspects. Eur Psychiatry 2009, 24(8):493-500.
29. Gawryluk J.W., Wang J.F., Andreazza A.C., Shao L., Young L.T. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol 2010, 16:1-8.
30. Herken H., Uz E., Ozyurt H., Söǧüt S., Virit O., Akyol O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 2001, 6:66-73.
31. Hu D., Serrano F., Oury T.D., Klann E. Aging-dependent alterations in synaptic plasticity and memory in mice that overexpress extracellular superoxide dismutase. J Neurosci 2006, 26:3933-3941.
32. Kapogiannis D., Mattson M.P. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. Lancet Neurol 2011, 10(2):187-198.
33. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., Mahadik S.P. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxide in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 2002, 58:1-10.
34. Kirkpatrick B., Buchanan R.W., McKenny P.D., Alphs L.D., Carpenter W.T. The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res 1989, 30:119-124.
35. Kirkpatrick B., Buchanan R.W., Ross D.E., Carpenter W.T. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry 2001, 58:165-171.
36. Kohen R., Nyska A. Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol Pathol 2002, 30:620-650.
37. Kuloglu M., Ustundag B., Atmaca M., Canatan H., Tezcan A.E., Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 2002, 20:171-175.
38. Kunz M., Gama C.S., Andreazza A.C., Salvador M., Cereser K.M., Gomes F.A., et al. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1677-1681.
39. Liu Y., Zhu B., Wang X., Luo L., Li P., Paty D.W., et al. Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of multiple sclerosis. J Neuroimmunol 2003, 139:27-35.
40. Lohr J.B., Browning J.A. Free radical involvement in neuropsychiatric illnesses. Psychopharmacol Bull 1995, 31(1):159-165.
41. Mahadik S.P., Evans D.R. Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications. Psychiatr Clin North Am 2003, 26(1):85-102.
42. Mahadik S.P., Mukherjee S., Scheffer R., Correnti E.E., Mahadik J.S. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol Psychiatry 1998, 43(9):674-679.
43. Matsuzawa D., Obata T., Shirayama Y., Nonaka H., Kanazawa Y., Yoshitome E., et al. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS One 2008, 3(4):e1944.
44. McCreadie R.G., MacDonald E., Wiles D., Campbell G., Paterson J.R. The Nithsdale schizophrenia surveys. XIV: plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and in normal subjects. Br J Psychiatry 1995, 167:610-617.
45. Mukerjee S., Mahadik S.P., Scheffer R., Correnti E.E., Kelkar H. Impaired antioxidant defense at the onset of psychosis. Schizophr Res 1996, 19:19-26.
46. Nagai T., Yamada K., Kim H.C., Kim Y.S., Noda Y., Imura A., et al. Cognition impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress. FASEB J 2003, 17:50-52.
47. Nicolle M.M., Gonzalez J., Sugaya K., Baskerville K.A., Bryan D., Lund K., et al. Signatures of hippocampal oxidative stress in aged spatial learning-impaired rodents. Neuroscience 2001, 107:415-431.
48. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol Rep 1962, 10:81-799.
49. Padurariu M., Ciobica A., Dobrin I., Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett 2010, 479:317-320.
50. Pazvantoglu O., Selek S., Okay I.T., Sengul C., Karabekiroglu K., Dilbaz N., et al. Oxidative mechanisms in schizophrenia and their relationship with illness subtype and symptom profile. Psychiatry Clin Neurosci 2009, 63:693-700.
51. Peet M., Horrobin D.F. E-E multicentre study group. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002, 36:7-18.
52. Pegoraro L.F., Dantas C.R., Banzato C.E., Fuentes D. Correlation between insight dimensions and cognitive functions in patients with deficit and nondeficit schizophrenia. Schizophr Res 2013 Mar, [Epub ahead of print]. 10.1016/j.schres.2013.02.041.
53. Radak Z., Kumagai S., Taylor A.W., Naito H., Goto S. Effects of exercise on brain function: role of free radicals. Appl Physiol Nutr Metab 2007, 32:942-946.
54. Raffa M., Mechri A., Othman L.B., Fendri C., Gaha L., Kerkeni A. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1178-1183.
55. Ranjekar P.K., Hinge A., Hegde M.V., Ghate M., Kale A., Sitasawad S., et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 2003, 121:109-122.
56. Reddy R.D., Yao J.K. Free radical pathology in schizophrenia: a review. Prostaglandins Leukot Essent Fatty Acids 1996, 55:33-43.
57. Reddy R., Sahebarao M.P., Mukherjee S., Murthy J.N. Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biol Psychiatry 1991, 30:409-412.
58. Reddy R., Keshavan M., Yao J.K. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res 2003, 62:205-212.
59. Simpson G.M., Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970, 212:11-19.
60. Singh O.P., Chakraborty I., Dasgupta A., Datta S. A comparative study of oxidative stress and interrelationship of important antioxidants in haloperidol and olanzapine treated patients suffering from schizophrenia. Indian J Psychiatry 2008, 50:171-176.
61. Sivrioglu E.Y., Kirli S., Sipahioglu D., Gursoy B., Sarandol E. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2007, 3:1493-1499.
62. Srivastava N., Barthwal M.K., Dalal P.K., Agarwal A.K., Nag D., Srimal R.C., et al. Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology (Berl) 2001, 158:140-145.
63. Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia, just the facts 4. Clinical features and conceptualization. Schizophr Res 2009, 110:1-23.
64. Ustundag B., Atmaca M., Kirtas O., et al. Total antioxidant response in patients with schizophrenia. Psychiatry Clin Neurosci 2006, 60:458-464.
65. Voineskos A.N., Foussias G., Lerch J., Felsky D., Remington G., Rajji T.K., et al. Neuroimaging evidence for the deficit subtype of schizophrenia. JAMA Psychiatry 2013 Mar, 6:1-9.
66. Yao J.K., Keshavan M.S. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal 2011, 15(7):2011-2035.
67. Yao J.K., Reddy R. Oxidative stress in schizophrenia: pathogenetic and therapeutic implications. Antioxid Redox Signal 2011, 15(7):1999-2002.
68. Yao J.K., Reddy R., McElhinny L.G., et al. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J Psychiatr Res 1998, 32:385-391.
69. Yao J.K., Reddy R.D., McElhinny L.G., van Kammen D.P. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res 1998, 80:29-39.
70. Yao J.K., Reddy R.D., McElhinny L.G., van Kammen D.P. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res 1998, 32:1-8.
71. Yao J.K., Reddy R., van Kammen D.P. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. J Psychiatr Res 2000, 97:137-151.
72. Yao J.K., Reddy R.D., van Kammen D.P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001, 15(4):287-310.
73. Zhang X.Y., Zhao D.F., Su M., Zhang P.Y. The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. J Clin Psychopharmacol 2001, 21:85-88.
74. Zhang X.Y., Zhou F., Zhang P.Y., Wu G.Y., Su J.M., Cao L.Y. A doubleblind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J Clin Psychiatry 2001, 62:878-883.
75. Zhang X.Y., Zhao D.F., Cao Y., Zhang P.Y., Wu G.Y., Shen Y.C. The effect of risperidone treatment on superoxide dismutase in schizophrenia. J Clin Psychopharmacol 2003, 23:128-131.
76. Zhang X.Y., Zhao D.F., He L., Wan C. A meta-analysis of oxidative stress markers in schizophrenia. Sci China Life Sci 2010, 53:112-124.
77. Zhang X.Y., Chen da C., Xiu M.H., Yang F.D., Tan Y.L., He S., et al. Thioredoxin, a novel oxidative stress marker and cognitive performance in chronic and medicated schizophrenia versus healthy controls. Schizophr Res 2013, 143:301-306.